Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RC-0315
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Qureight
Deal Size : Undisclosed
Deal Type : Collaboration
Remedy Cell, Qureight use AI in Phase 1b RC-0315 Trial for IPF Treatment
Details : The collaboration aims to validate RC-0315, which is being evaluated for treating patients suffering from idiopathic pulmonary fibrosis.
Product Name : RC-0315
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 12, 2025
Lead Product(s) : RC-0315
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Qureight
Deal Size : Undisclosed
Deal Type : Collaboration